ESPR (Esperion Therapeutics, Inc.) Stock Analysis - Analyst Ratings

Esperion Therapeutics, Inc. (ESPR) is a publicly traded Healthcare sector company. As of May 21, 2026, ESPR trades at $3.14 with a market cap of $805.76M and a P/E ratio of -225901000000000000.00. ESPR moved +0.16% today. Year to date, ESPR is -17.85%; over the trailing twelve months it is +244.45%. Its 52-week range spans $0.69 to $4.18. Analyst consensus is neutral with an average price target of $2.92. Rallies surfaces ESPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate ESPR?

7 analysts cover ESPR: 0 strong buy, 0 buy, 6 hold, 1 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $2.92.

ESPR Key Metrics

Key financial metrics for ESPR
MetricValue
Price$3.14
Market Cap$805.76M
P/E Ratio-225901000000000000.00
EPS$-0.00
Dividend Yield0.00%
52-Week High$4.18
52-Week Low$0.69
Volume7.50M
Avg Volume0
Revenue (TTM)$418.24M
Net Income$-7.42M
Gross Margin0.00%

ESPR Analyst Consensus

7 analysts cover ESPR: 0 strong buy, 0 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.92.

Latest ESPR News

Recent ESPR Insider Trades

  • Looker Benjamin sold 5.71K (~$15.43K) on Mar 17, 2026.
  • Koenig Sheldon L. sold 25.58K (~$69.55K) on Mar 17, 2026.
  • Halladay Benjamin sold 6.42K (~$17.38K) on Mar 17, 2026.

Common questions about ESPR

What do analysts rate ESPR?
7 analysts cover ESPR: 0 strong buy, 0 buy, 6 hold, 1 sell, and 0 strong sell. The consensus rating is neutral. The average price target is $2.92.
Does Rallies show ESPR price targets?
Yes. Rallies tracks ESPR analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is ESPR research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ESPR. It does not provide personalized investment advice.
ESPR

ESPR